Given the potential impact of FSH on cardiovascular risk (Hyman et al., 2000), more work is warranted to examine whether lowering FSH by means of hormone therapy is a viable strategy to reduce neuronal loss and vascular damage, which are risk factors for AD in turn (Alber et al., 2019). Here, BRD2 is linked to Alzheimer disease.